Safety and Efficacy of NY-ESO-1 Antigen-specific T-cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial

CONCLUSIONS: Adoptive immunotherapy with TBI-1301 to selectively target NY-ESO-1 positive tumor cells appears to be a promising strategy for the treatment of advanced or recurrent synovial sarcoma with acceptable toxicity.PMID:37792433 | DOI:10.1158/1078-0432.CCR-23-1456

Source: Cell Research - October 4, 2023 Category: Cytology Authors: Akira Kawai Mikiya Ishihara Tomoki Nakamura Shigehisa Kitano Shintaro Iwata Kohichi Takada Makoto Emori Koji Kato Makoto Endo Yoshihiro Matsumoto Shigeki Kakunaga Eiichi Sato Yoshihiro Miyahara Kunihiko Morino Shinya Tanaka Shuichi Takahashi Fujio Matsuo Source Type: research